Research peptides2 specifications

CJC-1295 with DAC

Name: CJC-1295 with DAC
Brand: SUN Peptides
SKU: CD2

COA on request

CJC-1295 with DAC is a modified GHRH analogue designed with a Drug Affinity Complex for covalent albumin association. Available vial strengths are shown as variants of one family.

Wholesale quote requiredPrice confirmed by sales

Choose specification

Selected SKU: CD2
Pack: 2 mg x 10 vials
Status: Available for inquiry

No payment is taken online. Sales confirms availability, documentation, shipping, and commercial terms.

Purity≥98%Estimated delivery: within one week after the order is placed.

COA is available on request

COA files are available in the document library; additional batch-specific documentation can be requested with your inquiry. Each batch is tested with HPLC purity analysis (≥98%). For MSDS or detailed storage protocols, please contact our sales team.

Order formatOne box accepted

DeliveryWithin one week after order

ShippingShipping and duties included

DocumentationCOA available on request

Research effects

As a long-acting growth hormone-releasing hormone (GHRH) analogue containing a Drug Affinity Complex (DAC), CJC-1295 with DAC significantly and sustainedly elevates plasma growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels. A Phase I clinical trial in healthy subjects demonstrated that a single intravenous injection produced dose-dependent elevations in GH levels lasting up to 6 days or longer. Users report increased muscle strength, reduced body fat, and improvements in sleep quality and skin elasticity. In

Efficacy

clinical studies, CJC-1295 with DAC has been confirmed to significantly increase lean body mass and improve body composition. Its long-acting properties suggest potential therapeutic value in addressing metabolic and body composition changes associated with GH deficiency or aging.

Research mechanism

CJC-1295 with DAC acts by binding to and activating GHRH receptors on the anterior pituitary, stimulating the cAMP/PKA signaling pathway to promote GH synthesis and release. The DAC component in its structure—a covalent binding moiety derived from human serum albumin—enables reversible binding to circulating albumin, significantly extending its in vivo half-life (approximately 6-8 days). This albumin-binding strategy slows renal clearance and protects against enzymatic degradation, achieving sustained pharmacological effects. Unlike the NO DAC version, the DAC-containing formulation induces sustained plateau-like GH elevation rather than pulsatile release. While this offers advantages in achieving more robust and prolonged anabolic effects, it also warrants more careful monitoring of long-term IGF-1 levels and glucose metabolic balance.

Product details

Key identity and handling information for the selected research material.

Material identity

Confirm the full modified sequence, reactive group, molecular mass, and intact-product assay rather than relying on the family name alone.

Storage guidance

Store unopened material in its original sealed packaging, protected from light, moisture, and repeated temperature changes. Follow the product label and batch document for the exact storage temperature. After opening or preparation, use only a validated laboratory storage protocol.

Quality review

Report a quality concern within 14 days of delivery with the order, batch details and available photos.

Resolution

When a quality claim is approved, choose a full refund or replacement shipment.

24/7 WhatsApp contact

Sales support remains available for product, documentation and wholesale inquiry follow-up.

CD22 mg x 10 vials